The U.S. antibiotics market, valued at USD 18.09 billion in 2024, is anticipated to grow at a CAGR of 3.4% from 2025 to 2034, with segment-wise performance revealing nuanced shifts in demand across product types, therapeutic classes, and end-user settings. The market is segmented primarily by drug class—beta-lactams, fluoroquinolones, macrolides, tetracyclines, and newer agents such as...
Greek 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)